

1 **Haematopoietic stem cell transplantation for CTLA4 deficiency**

2  
3 Mary A. Slatter MD<sup>a,b</sup>, Karin R. Engelhardt PhD<sup>b</sup>, Lauri M. Burroughs MD<sup>c,d</sup>, Peter D. Arkwright DPhil<sup>e</sup>,  
4 Zohreh Nademi PhD<sup>a,b</sup>, Suzanne Skoda-Smith MD<sup>c</sup>, David Hagin PhD<sup>c</sup>, Alan Kennedy PhD<sup>f</sup>, Dawn  
5 Barge PhD<sup>g</sup>, Terence Flood MD<sup>a</sup>, Mario Abinun PhD<sup>a,b</sup>, Robert F. Wynn MD<sup>e</sup>, Andrew R. Gennery  
6 MD<sup>a,b</sup>, Andrew J. Cant MD<sup>a,b</sup> David Sansom PhD<sup>f</sup>, Sophie Hambleton DPhil<sup>a,b</sup> and Troy R. Torgerson  
7 MD<sup>c</sup>

8  
9 a. Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK

10 b. Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle upon tyne University,  
11 UK.

12 c. University of Washington and Seattle Children's Hospital, Seattle, USA.

13 d. Fred Hutchinson Cancer Research Center, Seattle, USA.

14 e. University of Manchester, Royal Manchester Children's Hospital, Manchester, UK

15 f. UCL Institute of Immunity and Transplantation , Royal Free Hospital, London UK

16 g. Regional Immunology Laboratory, Newcastle upon Tyne, UK.

17  
18  
19  
20 Corresponding author:

21 Dr Mary Slatter, Ward 3, Level 4, Great North Children's Hospital, Queen Victoria Rd, Newcastle upon  
22 Tyne NE1 4LP

23 Email: [mary.slatter@nuth.nhs.uk](mailto:mary.slatter@nuth.nhs.uk)

24 Fax: 0191 2820497

25 Tel: 0191 2825234  
26  
27  
28  
29  
30

31 **Capsule summary**

32 Mutations in Cytotoxic T lymphocyte antigen 4 cause an immune dysregulation syndrome with  
33 disrupted T and B cell homeostasis. We report 8 patients treated by haematopoietic stem cell  
34 transplantation, 6 survived with resolution of symptoms.

35 **Keywords**

36 CTLA4, haematopoietic stem cell transplantation (HSCT), total parenteral nutrition (TPN)

37 **Word count 1139**

38

39 *To the Editor*

40 Pathogenic mutations in Cytotoxic T lymphocyte antigen 4 (*CTLA4*) behave in an autosomal dominant  
41 manner with incomplete penetrance, resulting in a complex immune dysregulation syndrome with  
42 disrupted T and B cell homeostasis<sup>1-3</sup>. Kuehn et al. identified 7 patients from 4 families with  
43 lymphoproliferation, organ infiltration, autoimmune cytopenias and B cell abnormalities<sup>1</sup>. Schubert et  
44 al. identified 14 patients from 6 families, of whom 11 had enteropathy and 10  
45 hypogammaglobulinaemia; other manifestations included granulomatous lymphocytic interstitial lung  
46 disease, respiratory infections, organ infiltration, cytopenias, lymphadenopathy, skin diseases,  
47 autoimmune thyroiditis, arthritis and one case of solid cancer<sup>2</sup>. There are no published reports of  
48 haematopoietic stem cell transplantation (HSCT) for this disorder. We report 8 patients with *CTLA4*  
49 haploinsufficiency who have undergone HSCT in 3 paediatric centres: the Great North Children's  
50 Hospital, Newcastle upon Tyne, UK (4 patients), Royal Manchester Children's Hospital, Manchester,  
51 UK (1 patient) and the University of Washington and Seattle Children's Hospital, USA (3 patients).

52

53 The diagnosis was made retrospectively in seven patients who underwent HSCT for life-threatening,  
54 treatment-resistant immune dysregulation and in one patient prospectively. Clinical and laboratory  
55 features are summarised (Table 1). Novel heterozygous variants in *CTLA4* were predicted to be  
56 deleterious in all cases (Table 2), confirmed by functional testing in a recombinant system for the  
57 missense variants identified in patients 1-5 (Figure 1 and supplementary methods). Patient 6 has a  
58 different amino acid substitution at the same residue as patient 5 which was not tested separately.  
59 Sequencing of *CTLA4* cDNA confirmed that the mutation identified in patients 7 and 8 led to skipping  
60 of exon 3 with splicing of exon 4 to exon 2 leading to a frameshift and premature termination, deleting  
61 the transmembrane and intracellular domains of *CTLA4* and abrogating protein expression (data not  
62 shown).

63

64 Patient 1 had arthritis, neutropenia and thrombocytopenia, lymphadenopathy and abdominal pain.  
65 This patient was offered HSCT due to ongoing autoimmunity and risk of lymphoma as his father had  
66 complex autoimmune disease and died following autologous HSCT for non-Hodgkin's lymphoma.  
67 Patient 2 had thrombocytopenia, associated bleeding, neutropenia and lymphoid hyperplasia in lungs,  
68 lymph nodes and brain, refractory to immunomodulatory therapy. Patient 3 had autoimmune

69 haemolytic anaemia and thrombocytopenia from the age of 4 and developed enteropathy and  
70 bronchiectasis. She had severe side effects from steroid therapy. Her mother was also affected with  
71 cytopenias, hypothyroidism and eczema. Patient 4 (sibling to patient 3) was well until he presented  
72 with inflammatory colitis and Hodgkin lymphoma (inguinal and para-aortic region) at age 16. Because  
73 of his sibling's history, *CTLA4* haploinsufficiency was confirmed by both genetic and protein level  
74 testing, the only patient in this cohort to have an identified mutation prior to HSCT. His fulminant  
75 diarrhoea responded to a combination of prednisolone, sirolimus and Belatacept and his Hodgkin  
76 Disease was successfully treated with three cycles of chemotherapy prior to transplantation. Patient 5  
77 had brittle diabetes from the age of 2 with severe enteropathy requiring parenteral nutrition (TPN),  
78 cytopenias necessitating splenectomy and cholecystectomy, recurrent deep vein thrombosis,  
79 bronchiectasis, vitiligo and alopecia and severe side effects from steroid therapy. He was refractory to  
80 treatment including Alemtuzumab, Infliximab and Adalimumab and his mother died due to a  
81 gastrointestinal lymphoma. Patient 6 had trilineage cytopenias, enteropathy with pancreatic  
82 insufficiency since age 7 requiring TPN, and diabetes. In addition he had recurrent infections  
83 including pulmonary aspergillosis. Patient 7 had enteropathy, cytopenias, and juvenile idiopathic  
84 arthritis beginning in childhood.

85

86 All 8 patients received steroids and a calcineurin inhibitor prior to transplant, and all except patients 3  
87 and 4 had high dose IVIg and rituximab as immunomodulatory therapy. Patient 4 had replacement  
88 IVIg because of his hypogammaglobulinemia but no rituximab. Consent for HSCT and genetic work-  
89 up was obtained according to local centre and EBMT guidelines. All received well-matched unrelated  
90 donor grafts following reduced intensity conditioning. Five patients (1, 2, 5, 6, and 8) had peripheral  
91 blood HSC grafts and received cyclosporine and mycophenolate mofetil (MMF) for graft versus host  
92 disease (GvHD) prophylaxis. Three (3, 4, and 7) received bone marrow HSC grafts and had  
93 cyclosporine alone, cyclosporine and MMF, or methotrexate and tacrolimus.. Patient 6 had  
94 prednisolone, sirolimus and Belatacept until 8 days prior to transplant. Transplant characteristics are  
95 summarised in Table 3.

96

97 Neutrophil engraftment (1st day of Neutrophils greater than  $0.5 \times 10^9/l$ ) ranged from D+13 to D+21  
98 and platelets were greater than  $50 \times 10^9/l$  between D+13 and Day+15 post HSCT. Patients 1 and 8

99 have stable mixed donor chimerism of  $\geq 85\%$  in all cell lineages and patients 3, 4, 6, and 7 have 100%  
100 donor chimerism. Six of 8 patients are alive and well. Patient 2 died with transplant-related mortality of  
101 severe acute gut GvHD. Patient 5 did well post HSCT, became TPN-independent after 5 months, but  
102 unfortunately died from diabetic ketoacidosis 2.5 years post HSCT. Both of these patients had 100%  
103 donor chimerism. Patient 1 had CMV reactivation early post HSCT and autoimmune haemolytic  
104 anaemia 6 months post HSCT, which responded to steroids; he is now off all medication. Patient 3  
105 had an uncomplicated transplant course and is also off all medication. Patient 4 had a relapse of  
106 inflammatory colitis with 10 - 20 stools/day on day 2 after transplant but this was controlled by day 10  
107 with steroids and Belatacept which have both been discontinued. He is now well 14 weeks post-  
108 transplant. Patient 6 remains on sirolimus for oral and ocular chronic GvHD which have resolved.  
109 Patient 7 had chronic oral and skin GvHD and she is now off all immune suppression. Patient 8 has  
110 had no GvHD but continues on MMF and cyclosporine for GvHD prophylaxis 4 months after  
111 transplant. In summary 5 of 8 patients experienced GvHD despite having well-matched donors and  
112 receiving Alemtuzumab in 2. The high levels of inflammation in which these patients enter the HSCT  
113 process may promote the development of alloreactivity and so future patients are likely to benefit from  
114 either enhanced pre-HSCT immunosuppression, or more aggressive post-HSCT GvHD prophylaxis.  
115 Seven of 8 patients had complete resolution of severe enteropathy and cytopenias following HSCT,  
116 however diabetes is irreversible, highlighting the importance of early recognition and treatment.  
117 Improved outcome after HSCT for autoimmune diseases<sup>4</sup> and for children with other non-malignant  
118 disorders following reduced intensity conditioning<sup>5,6</sup> makes HSCT an attractive option for severe  
119 cases and our series suggests a similar transplant related mortality (1 of 8 patients) to that for other  
120 immune disorders. Other therapeutic options proposed for *CTLA4* deficient patients include soluble  
121 *CTLA4* fusion proteins (abatacept and belatacept), which bind to CD80 and CD86 and inhibit immune  
122 activation<sup>7</sup>. These were tried with probable benefit in the only patient to receive a molecular  
123 diagnosis prior to HSCT, but did not alter the indication for transplant which was his non-Hodgkin's  
124 lymphoma. *CTLA4* haploinsufficiency shows a variable phenotype and further studies are needed to  
125 guide treatment selection including which patients could benefit from *CTLA4*-ligand-targeted  
126 immunomodulation vs. HSCT, optimal timing of HSCT and long-term outcome post-HSCT.

127

128 Mary A. Slatter MD<sup>a,b</sup>

129 Karin R. Engelhardt PhD<sup>a</sup>  
130 Lauri M. Burroughs MD<sup>c,d</sup>  
131 Peter D. Arkwright DPhil<sup>e</sup>  
132 Zohreh Nademi PhD<sup>a,b</sup>,  
133 Suzanne Skoda-Smith MD<sup>c</sup>  
134 David Hagin PhD<sup>c</sup>  
135 Alan Kennedy PhD<sup>f</sup>  
136 Dawn Barge PhD<sup>g</sup>  
137 Terence Flood MD<sup>a</sup>  
138 Mario Abinun PhD<sup>a,b</sup>  
139 Robert F. Wynn MD<sup>e</sup>  
140 Andrew R. Gennery MD<sup>a,b</sup>  
141 Andrew J. Cant MD<sup>a,b</sup>  
142 David Sansom PhD<sup>f</sup>  
143 Sophie Hambleton DPhil<sup>a,b</sup> and Troy R. Torgerson MD<sup>c</sup>

144

145 a. Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK

146 b. Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle upon tyne University,

147 UK.

148 c. University of Washington and Seattle Children's Hospital, Seattle, USA.

149 d. Fred Hutchinson Cancer Research Center, Seattle, USA.

150 e. University of Manchester, Royal Manchester Children's Hospital, Manchester, UK

151 f. UCL Institute of Immunity and Transplantation , Royal Free Hospital, London UK

152 g. Regional Immunology Laboratory, Newcastle upon Tyne, UK.

153

154

155 **Acknowledgements**

156 Funding from the following grants contributed to this work: NIH R13 AI094943, NIH U54 AI082973,  
157 and NIH P01 HL122173. One of the U.S. patients was enrolled on a clinical trial supported in part by  
158 NIH grant P01 HL122173, as well as research funding from Medac, GmbH (Hamburg, Germany). In  
159 addition, Medac, GmbH provided Treosulfan for the study in the U.S.

160

161


162

163 **References**

- 164 1.Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT et al. Immune dysregulation in  
165 human subjects with heterozygous germline mutations in CTLA4. *Science* 2014 Sep;  
166 345(6204):1623-1627
- 167 2.Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A et al. Autosomal dominant immune  
168 dysregulation syndrome in humans with CTLA4 mutations. *Nat Med.* 2014 Dec;20(12):1410-6.
- 169 3.Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by  
170 costimulation-dependent activation of CD4+ T cells. *Immunity* 1997;(7):885-95
- 171 4. Snowden JA, Pearce RM, Lee J, Kirkland K, Gilleece M, Veys P et al; BSBMT Clinical Trials  
172 Committee. Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases:  
173 analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data  
174 registry 1997-2009.*Br J Haematol.* 2012 Jun;157(6):742-6.
- 175 5. Rao K, Amrolia PJ, Jones A, Cale CM, Naik P, King D et al. Improved survival after unrelated donor  
176 bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity  
177 conditioning regimen. *Blood* 2005 105; 879-885
- 178 6. Burroughs LM, Nemecek ER, Torgerson TR, Storer BE, Talano JA, Domm J et al. Treosulfan-  
179 based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective  
180 multicenter trial. *Biol Blood Marrow Transplant.* 2014 Dec;20(12):1996-2003.
- 181 7. Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C et al. AUTOIMMUNE DISEASE.  
182 Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept  
183 therapy. *Science.* 2015 Jul 24;349(6246):436-40



**Figure 1**



**Figure 1** - Mutations in CTLA-4 affect ligand uptake. CHO cells expressing WT or mutant forms of CTLA-4 were cultured in the presence of CD80-Ig, CD86-Ig or an anti-CTLA-4 antibody. Cells were analysed for their ability to uptake ligand or antibody at 37°C relative to total cellular CTLA-4 expression. Each mutant was then normalised to CTLA-4 WT expressing cells.

**Table 1 - Patient Characteristics**

Patient/ Gender	Heterozygous change in CTLA-4	Lymphocyte subsets* cells/uL (Normal range)	Immunoglobulins g/L (Normal range)	Age at onset Clinical features	Family history
1 M	c.518G>A p.G173E	14 years CD3 1325 (800-3500) CD4 771 (400-1200) Naïve CD4 225 CD8 531 (200-1200) Naïve CD8 305 CD3CD25 10% CD3DR 16% NK 59 (70-1200) CD19 296 (200-600)	14 years IgG 10.9 (3.8-15.2) IgA 0.30 (0.64-2.58) IgM 0.76 (0.43-1.9)  Pre Ig Pre RTX	1.5 years <ul style="list-style-type: none"> <li>Autoimmune pancytopenia</li> <li>Recurrent abdominal pain</li> <li>Arthritis</li> </ul>	Father: Immune dysregulation Cytopenias Lymphoma
2 M	c.529T>G p.Y177D	13 years CD3 934 (800-3500) CD4 436 (400-1200) Naïve CD4 nil CD8 371 (200-1200) Naïve CD8 nil CD3CD25 11% CD3DR 38% NK 140 (70-1200) CD19 2700 (200-600)	13 years IgG 13.5 (3.8-15.2) IgA 0.86 (0.64-2.97) IgM 1.06 (0.43-1.9)  Pre Ig Pre RTX	10 years <ul style="list-style-type: none"> <li>ITP and autoimmune neutropenia</li> <li>Reactive lymphoid hyperplasia - lymph nodes, lung, frontal lobe brain</li> </ul>	nil
3 F	c.437G>T p.G146V	7 years CD3 738 (800-3500) CD4 284 (400-1200) Naïve CD4 nil CD8 339 (200-1200) Naïve CD8 nil	7 years IgG 3.54 (3.8-15.2) IgA 0.41 (0.64-2.58) IgM 0.21 (0.43-1.9)  Pre Ig	5 years <ul style="list-style-type: none"> <li>Autoimmune cytopenias</li> <li>Enteropathy</li> <li>Bronchiectasis</li> </ul>	Mother: Enteropathy Evan's syndrome  Brother: Patient #4

		CD3CD25 15% CD3DR 31% NK 160 (70-1200) CD19 0 (200-600)	No RTX		
4 M	c.437G>T p.G146V	16 years CD3 190 (622-2402) CD4 124 (24-406) CD8 49 (500-1500) NK 11 (109-897) CD19 9 (120-645)	16 years IgG 4.92 (6.0-16.0) IgA 1.33 (0.8-2.8) IgM 0.24 (0.5-2.0)  Pre Ig No RTX	16 years <ul style="list-style-type: none"> <li>• Enteropathy</li> <li>• Hodgkin Disease (mixed cellularity) treated with Euronet PHL-C1 Hodgkin's Lymphoma 2007 protocol, received 3 courses of ABVD</li> </ul>	Mother: Enteropathy Evan's syndrome  Sister: Patient #3
5 M	c.410C>G p.P137R	18 years CD3 2842 (690-2540) CD4 2350 (410-1590) Naïve CD4 682 CD8 492 (190-1140) Naïve CD8 455 CD3CD25 21% CD3DR 15% NK 114 (90-590) CD19 0 (90-660)	18 years IgG 8.84 (5.8-15.4) IgA 0.62 (0.64-2.07) IgM 1.49 (0.24-1.9)  On Ig Post RTX	2 years <ul style="list-style-type: none"> <li>• Autoimmune cytopenias</li> <li>• Enteropathy –PN dependent for 5 years</li> <li>• IDDM</li> <li>• Exocrine pancreatic insufficiency</li> <li>• Bronchiectasis</li> <li>• Recurrent deep vein thromboses</li> </ul>	Mother: Lymphoma  Brother: Autoimmune gut disease  Sister: Arthritis Autoimmune thyroiditis
6 M	c.410C>T p.P137L	13 years CD3 592 (800-3500) CD4 402 (400-2100) CD8 171 (200-1200) CD3CD25 6% CD3DR 35% NK 100 (0-771) CD19 271 (200-600)	13 years IgG 7.94 (6.0-15.8) IgA 0.40 (0.38-2.00) IgM 0.61 (0.35-2.52)  Pre Ig Pre RTX	7 years <ul style="list-style-type: none"> <li>• Autoimmune cytopenias</li> <li>• Enteropathy</li> <li>• Exocrine pancreatic insufficiency</li> <li>• IDDM</li> <li>• Recurrent infections: Sinusitis &amp; Streptococcal pharyngitis. Pulmonary Aspergillosis.</li> <li>• Renal insufficiency</li> </ul>	Father: Hashimoto thyroiditis  Mother: Autoimmune thyroiditis  Maternal Grandmother: Persistent diarrhea
7 F	c.567+6T>G	28 years	28 years	1-2 years	Father:

	p.D153Afs*21 (Splicing)	CD3 622 (700-2100) CD4 496 (300-1400) CD8 112 (200-900) CD3DR 11% NK 56 (0-771) CD19 0 (100-500)	IgG 0.93 (5.4-16.8) IgA 0.68 (0.74-2.61) IgM 1.51 (0.40-1.95)  Pre Ig Pre Rtx	<ul style="list-style-type: none"> <li>• ITP &amp; Autoimmune hemolytic anemia</li> <li>• Enteropathy/lymphocytic colitis</li> <li>• Hypocalcemia, Vit D deficiency, Osteoporosis</li> <li>• Interstitial lung disease</li> <li>• Juvenile rheumatoid arthritis</li> <li>• Eczema</li> </ul>	ITP  Sister: Patient #8
8 F	c.567+6T>G p.D153Afs*21 (Splicing)	26 years CD3 648 (700-2100) CD4 464 (300-1400) Naïve CD4 33 CD8 160 (200-900) Naïve CD8 54 CD3DR 23% NK 48 (0-771) CD19 88 (100-500)	26 years IgG 4.9 (5.4-16.8) IgA 0.27 (0.74-2.61) IgM 0.84 (0.40-1.95)  Pre Ig Pre Rtx	23 years <ul style="list-style-type: none"> <li>• Interstitial Lung Disease (“Nodular Lymphoid Hyperplasia”)</li> <li>• Transverse myelitis</li> <li>• Recurrent white matter and brainstem lesions with oligoclonal bands and elevated IgG index</li> <li>• Arthritis</li> </ul>	Father: ITP  Sister: Patient #7

Abbreviations: ITP=Idiopathic thrombocytopenic purpura, IDDM= Insulin dependent diabetes mellitus, PN= parenteral nutrition, naïve CD4 = CD3+CD4+CD27+CD45RA+, naïve CD8 = CD3+CD4-CD27+CD45RA+, Ig = immunoglobulin therapy, RTX = Rituximab, ABVD: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine

\*Lymphocyte subset results at first visit to specialized immunology center

**Table 2 - Variants**

Patient/ Gender	Heterozygous change in CTLA-4	Known mutation*	SIFT prediction	PROVEAN prediction	Mutation Taster prediction	PolyPhen-2 prediction	PON-P2	CADD score	Affected domain
1/M	c.518G>A p.G173E	No	Damaging	Neutral	Disease causing	Probably damaging (score: 0.978)	Unknown (score: 0.369)	1.955	Transmembrane domain
2/M	c.529T>G p.Y177D	No	Damaging	Deleterious	Disease causing	Probably damaging (score: 0.998)	Unknown (score: 0.722)	4.201	Transmembrane domain
3/F, 4/M	c.437G>T p.G146V	No	Damaging	Deleterious	Disease causing	Probably damaging (score: 1.000)	Pathogenic (score: 0.872)	2.791	Ligand-binding domain
5/M	c.410C>G p.P137R	No	Damaging	Deleterious	Disease causing	Probably damaging (score: 1.000)	Pathogenic (score: 0.869)	2.664	Ligand-binding domain
6/M	c.410C>T p.P137L	No	Damaging	Deleterious	Disease causing	Probably damaging (score: 1.000)	Pathogenic (score: 0.804)	3.058	Ligand-binding domain
7/F, 8/F	c.567+6T>G p.D153Afs*21	No	N/A	N/A	N/A	N/A	N/A	N/A	Transmembrane & Intracellular domains

\*According to ESP6500, cg69, dbSNP, 1000G and ExAC databases.

N/A = Not applicable due to large deletion/frameshift created by aberrant mRNA splicing of exon 4 to exon 2 (exon 3 is skipped).

**Table 3 - Transplant characteristics**

Patient/ Gender	Age at HSCT (Years)	Year of HSCT	Conditioning	Donor source/ HLA matching	GVHD Prophylaxis	GvHD	Chimerism	Outcome/ Follow up
1 M	16	2010	Alem, Flu, Treo	PBSC 10/10	MMF/CSP	None Off immune suppression	CD3+ 90% CD19+ 95% CD15+ 96%	Alive and well 4.75 years
2 M	15	2008	Alem, Flu, Mel	PBSC 10/10	MMF/CSP	Acute Grade IV gut	100%	Died 4 months (GvHD)
3 F	10	2005	Alem, Flu, Mel	BM 10/10	CSP	None Off immune suppression	100%	Alive and well 10.2 years
4 M	17	2015	Alem, Flu, Treo, Thio	BM 10/10	MMF/CSP	Flare of autoimmune colitis D+2 - +10. Treated with methylpredisolone and belatacept. Remains on CSP alone	100%	Alive and well, discharged from hospital 3.5 months
5 M	20	2008	Alem, Flu, Mel	PBSC 10/10	MMF/CSP	Acute Grade II skin resolved. Immune suppression stopped	100%	Died 2.5 years (DKA)
6 M	17	2013	Flu, TBI	PBSC 10/10	MMF/CSP	Acute Grade III skin and gut resolved Chronic Oral and ocular GvHD.	CD3+ 100% CD19+ 100% CD56+ 100% CD33+ 100%	Alive and well 2.0 years

						Continues on sirolimus and physiologic prednisone		
7 F	30	2011	rATG, Flu, Treo	BM 10/10	MTX/TAC	Acute Grade II skin and gut GVHD resolved Chronic oral and skin GVHD resolved. Off immune suppression	CD3+ 100% CD33+ 100%	Alive and well 4 years
8 F	32	2015	Flu, TBI	PBSC 10/10	MMF/CSP	None. Continues on tapering doses of MMF/CSP.	CD3+ 85% CD56+ 100% CD33+ 100%	Alive and well 4 months

Abbreviations: Alem = Alemtuzumab total dose 1.0mg/kg, Flu = Fludarabine total dose 150mg/m<sup>2</sup>, Mel = Melphalan total dose 140mg/m<sup>2</sup>, rATG = rabbit anti-thymocyte globulin total dose 6.0 mg/kg, Thio - Thiotepa total dose 10mg/kg, TBI = total body irradiation total dose 4 Gy , Treo = Treosulfan total dose 42g/m<sup>2</sup>, MTX = Methotrexate, CSP = Cyclosporine, TAC = Tacrolimus, MMF = Mycophenolate Mofetil, PBSC = peripheral blood stem cells, BM = bone marrow, GvHD=Graft versus host disease, DKA = diabetic ketoacidosis